Depomed Initiates Phase I Trial for DM-1992 Program in PD
Depomed Initiates Phase I Trial for DM-1992 Program in Parkinson’s Disease Following Positive Results of Preclinical Studies Sponsored by The Michael J. Fox Foundation
CentralDaily.com / Tuesday, Feb. 17, 2009 MENLO PARK, Calif. — Depomed, Inc. (NASDAQ / DEPO) today announced that it has dosed the first patient in a Phase I trial for its DM-1992 program in Parkinson’s disease based on positive results from preclinical studies sponsored by The Michael J. Fox Foundation for Parkinson’s Research. DM-1992 is an investigative novel gastric retentive extended-release dosage form of Levodopa/Carbidopa, a marketed therapy used in the treatment of Parkinson’s disease. Click above to find the source |
All times are GMT -5. The time now is 06:05 PM. |
Powered by vBulletin Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.
vBulletin Optimisation provided by
vB Optimise v2.7.1 (Lite) -
vBulletin Mods & Addons Copyright © 2024 DragonByte Technologies Ltd.